Posted on August 12, 2020 by Sitemaster
We have recently learned that Movember conducted a major landscape analysis of unmet research needs in prostate cancer that started back in 2017 and ran through 2019 but just got published in 2020. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: analysis, landscape, Movember, need, priority, research | Leave a comment »
Posted on November 1, 2018 by Sitemaster
We have probably all heard terms like “liquid biopsy” and “genetic screening” and “cell-free” DNA analysis over the past few years. These are all terms related to the use of genetic and genomic information to “personalize” cancer diagnosis and its management. And they are potentially a huge big deal. But, … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: analysis, cancer, detection, DNA, Management, monitoring, risk | 4 Comments »
Posted on June 16, 2017 by Sitemaster
A new paper in a new journal argues that all men diagnosed with advanced forms of prostate cancer should now, routinely, be undergoing tumor and germline DNA profiling … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: analysis, genetic, genomic, targeted, testing, therapy | 2 Comments »
Posted on January 26, 2017 by Sitemaster
So the other morning your sitemaster learned that a relatively new FirstWord Therapy Report had come out that dealt with future use of biopharmaceuticals in the treatment of progressive and advanced prostate cancer. … READ MORE …
Filed under: Drugs in development | Tagged: analysis, development, drug, information, new, ongoing | 4 Comments »
Posted on August 5, 2016 by Sitemaster
A new paper from researchers at the University of Santa Cruz and UCLA, just published in the journal Cell, has laid out the beginnings of a method to identify personalizable forms of therapy for men with metastatic forms of prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: analysis, individualized, metastatic, personalized, therapy | 1 Comment »
Posted on April 22, 2013 by Sitemaster
A new study, to published shortly on-line in Cancer, suggests that significant alterations to the “copy numbers” of the PTEN and MYC genes in men with prostate cancer are strongly associated with risk for prostate cancer-specific mortality. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: alteration, analysis, copy number, gene, mortality, MYC, PTEN, risk | 3 Comments »
Posted on October 17, 2011 by Sitemaster
For those who are really “into” the probabilistic statistics of prostate cancer decision analysis, we recommend a recent article in the journal Medical Decision-Making. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: analysis, decision, Markov, model, PSA, screening | 7 Comments »